Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Integrated PK/efficacy, safety, and immunogenicity study of JPB898 versus Opdivo in combination with Yervoy in advanced melanoma
2023-507865-24-00Phase 3Completed
- Sponsor
- Hexal AG
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 27
01
Overview
Phase 3, randomised trial in melanoma comparing JPB898 + Yervoy with Opdivo + Yervoy (2 arms). Primary endpoints: Primary pharmacokinetic similarity endpoints, Primary efficacy endpoint and 1 more. Started Jul 2024; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2023-507865-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507865-24-00.